ROS-Fueled Nanomotors Burrow Into Cartilage to Deliver Metformin and Ease Osteoarthritis Pain
Self-propelled nanomotors use excess joint ROS as fuel to penetrate cartilage, release metformin, and protect chondrocytes in mouse osteoarthritis.
Résumé
Osteoarthritis drugs injected into the joint are cleared quickly and barely penetrate dense cartilage. Researchers built Janus nanomotors with a platinum-coated gold 'engine' and a porous organosilica 'container' holding metformin. The engine mimics SOD and catalase, converting excess reactive oxygen species (ROS) in the joint into water and oxygen, which propels the particles deeper into tissue. In cell studies, the metformin-loaded nanomotors lowered ROS, reduced cartilage-degrading enzymes, and gave longer-lasting protection than free metformin, partly through the NRF2/KEAP1 pathway. In mice with surgically induced osteoarthritis, they retained longer in the joint, reduced joint temperature and ROS signal, and, according to the authors, suppressed pain-related signaling in dorsal root ganglia. The work is preclinical and early-stage.
Résumé détaillé
Osteoarthritis (OA) is increasingly viewed as a disease driven by chronic low-grade inflammation and oxidative stress rather than simple wear and tear. Existing options such as NSAIDs and corticosteroid injections carry risks or only relieve symptoms. Metformin can lower reactive oxygen species (ROS) and has shown pain benefit in overweight patients with knee OA, but delivery is a problem: systemic dosing lacks joint specificity, and injected drugs are cleared quickly and cannot easily cross dense, negatively charged cartilage.
The researchers built Janus nanomotors about 170 nm in size. One side is a gold nanoparticle with a ~10 nm platinum shell that acts as an engine with SOD- and catalase-like activity, breaking down H2O2 into water and oxygen and generating propulsion. The other side is a periodic mesoporous organosilica nanocube loaded with metformin (36 µmol per mg), which released the drug over about 8 days in vitro. In H2O2 solution, the nanomotors moved faster as fuel concentration rose (mean speed 3.85 to 6.25 µm/s from 0 to 20 mM), and propulsion was only modestly reduced in culture medium. They also scavenged hydroxyl radicals and produced oxygen.
In rodent joints, the nanomotors penetrated deeper into cartilage than free fluorescent dye, especially after DMM surgery. ICP-MS showed gradual clearance over 21 days, with higher early retention in OA joints. Imaging showed the particles persisted about 7 days in sham joints and about 14 days in OA joints, whereas free dye cleared rapidly. In primary mouse chondrocytes and RAW264.7 macrophages, the metformin-loaded nanomotors (NM@MET) showed low cytotoxicity (viability about 90% or higher at 1 mg/mL), reduced ROS, lowered Mmp3 and Mmp13, and preserved Col2a1 and Sox9 after IL-1β challenge. They also reduced IL-1β and IL-6 in M1-polarized macrophages. Protection lasted about five days, whereas free metformin's effect faded.
RNA sequencing pointed to glutathione metabolism, NADPH oxidase complex, and neuroactive ligand-receptor pathways. Western blots showed the nanomotors modulated NRF2, HO1, and KEAP1, and the NRF2 inhibitor ML385 partly reversed the protective effect, implicating NRF2 signaling. In DMM mice injected weekly, NM@MET gave the lowest knee temperature (35.4°C versus 36.3°C with PBS) and weakest ROS luminescence. Micro-CT assessed osteophytes and subchondral sclerosis. The abstract also reports reduced DRG nociceptive signaling, less pain, and better mobility, though the supplied full text is truncated before these results.
Caveats: this is mouse and cell work only, using a surgical OA model. The text provided cuts off before the full histology, pain, and safety data, and long-term fate of gold, platinum, and silica components in the body needs study. Human translation is unproven.
Principales conclusions
- Platinum-gold/organosilica Janus nanomotors use joint ROS as fuel, with speed rising from 3.85 to 6.25 µm/s as H2O2 increased from 0 to 20 mM.
- Nanomotors penetrated deeper into cartilage than free dye and stayed in OA joints about 14 days versus about 7 days in sham joints.
- NM@MET lowered ROS, Mmp3 and Mmp13 and preserved Col2a1 and Sox9 in IL-1β-stimulated chondrocytes, with effects lasting five days versus fading free metformin.
- Chondroprotection involved NRF2/KEAP1 signaling; the NRF2 inhibitor ML385 partially reversed NM@MET's benefits.
- In DMM mice, NM@MET gave the lowest knee temperature and ROS signal; the authors report reduced DRG nociceptive signaling and pain.
Méthodologie
The team synthesized and characterized AuNP@Pt-PMO Janus nanomotors (TEM, SEM, EDS, ESR, trajectory tracking), then tested them in mouse chondrocytes and RAW264.7 macrophages using viability, ROS, qPCR, western blot, RNA-seq, and NRF2 inhibition. In vivo, they used DMM-induced OA in mice (with rat cartilage penetration assays), weekly intra-articular injections, thermography, L-012 ROS imaging, and micro-CT, with PBS, NM, MET, and NM@MET groups.
Limites de l'étude
Evidence comes from cell cultures and a surgical mouse model, with limited sample details visible and the supplied text truncated before the complete histological, pain behavior, and safety results. Long-term biodistribution and clearance of gold, platinum, and silica components, immunogenicity, and efficacy in larger animals or humans remain untested; propulsion in vivo is inferred from penetration data rather than directly observed.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :